Head-To-Head Contrast: Oncolytics Biotech, Inc. (USA) (ONCY) and ContraFect Corporation (CFRX)

Oncolytics Biotech, Inc. (USA) (NASDAQ: ONCY) and ContraFect Corporation (NASDAQ:CFRX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends and valuation.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Oncolytics Biotech, Inc. (USA) and ContraFect Corporation, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oncolytics Biotech, Inc. (USA) 0 0 0 0 N/A
ContraFect Corporation 0 1 1 0 2.50

ContraFect Corporation has a consensus target price of $5.00, suggesting a potential upside of 390.20%. Given ContraFect Corporation’s higher possible upside, analysts clearly believe ContraFect Corporation is more favorable than Oncolytics Biotech, Inc. (USA).

Risk & Volatility

Oncolytics Biotech, Inc. (USA) has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500. Comparatively, ContraFect Corporation has a beta of -0.84, meaning that its stock price is 184% less volatile than the S&P 500.

Profitability

This table compares Oncolytics Biotech, Inc. (USA) and ContraFect Corporation’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Oncolytics Biotech, Inc. (USA) N/A -161.95% -123.71%
ContraFect Corporation N/A -113.71% -53.03%

Institutional and Insider Ownership

24.5% of ContraFect Corporation shares are owned by institutional investors. 9.3% of ContraFect Corporation shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Oncolytics Biotech, Inc. (USA) and ContraFect Corporation’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Oncolytics Biotech, Inc. (USA) N/A N/A N/A ($0.11) -4.54
ContraFect Corporation N/A N/A -$28.53 million ($0.23) -4.43

Oncolytics Biotech, Inc. (USA) is trading at a lower price-to-earnings ratio than ContraFect Corporation, indicating that it is currently the more affordable of the two stocks.

Summary

ContraFect Corporation beats Oncolytics Biotech, Inc. (USA) on 6 of the 8 factors compared between the two stocks.

Oncolytics Biotech, Inc. (USA) Company Profile

Oncolytics Biotech Inc. is a development-stage company. The Company is focused on the development of REOLYSIN, its cancer therapeutic. The Company’s clinical program is made up of a registration program that includes muscle-invasive bladder cancer and glioma cancer, over six randomized Phase II clinical trials and approximately six other investigative clinical trials. The Company focuses on the registration of REOLYSIN in approximately two indications, including the neoadjuvant treatment of muscle-invasive bladder cancer and the treatment of glioblastoma. The Company has conducted a single arm United States Phase II non-small cell lung cancer (NSCLC) trial and a single arm United States Phase II pancreatic cancer trial for REOLYSIN. The Company is also engaged in conducting a Phase Ib trial for REOLYSIN and chemotherapy in combination with pembrolizumab in its Checkpoint Inhibitor Program.

ContraFect Corporation Company Profile

ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible Staph aureus; and CF-404, a combination of human monoclonal antibodies (mAbs) for the treatment of life-threatening seasonal and pandemic varieties of human influenza. The company has a collaboration research agreement with The Rockefeller University to identify new lysin therapeutic candidates targeting Gram-negative bacteria; and license agreement with Trellis Bioscience LLC for mAbs in the field of influenza. ContraFect Corporation was founded in 2008 and is headquartered in Yonkers, New York.

Receive News & Ratings for Oncolytics Biotech Inc. (USA) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech Inc. (USA) and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply